(Total Views: 693)
Posted On: 10/27/2020 10:40:23 AM
Post# of 153903
UK pricing and marketing
From a report by the House Ways and Means Committee last year, it looks like the average drug pricing for the UK is about 3-4 times less than the US. So that would be $8,000-12,000 per patient per year. With 100,000 patients total in the UK, 5% on leronlimab would be around $50M a year although I have no idea what kind of adoption we could expect as part of combo therapy, or if off-label mono gains traction.
We would still need a deal to have a local salesforce market leronlimab to doctors but I don't imagine it would take much to reach the necessary doctors with the relatively small patient population and probable concentration of patients in London.
From a report by the House Ways and Means Committee last year, it looks like the average drug pricing for the UK is about 3-4 times less than the US. So that would be $8,000-12,000 per patient per year. With 100,000 patients total in the UK, 5% on leronlimab would be around $50M a year although I have no idea what kind of adoption we could expect as part of combo therapy, or if off-label mono gains traction.
We would still need a deal to have a local salesforce market leronlimab to doctors but I don't imagine it would take much to reach the necessary doctors with the relatively small patient population and probable concentration of patients in London.
(0)
(0)
